Most Recent
The Australian Securities and Investments Commission has banned a financial adviser for five years for failing to act in his clients' best interests, the second action taken by the corporate regulator through a project that uses data to target bad life insurance advisers.
In a win for aviation services company Aerocare, a court on Friday ruled the company's bid for review of its controversial split-shift rosters was not an abuse of process as two unions had argued.
Westpac was responsible for the conduct of its in-house financial planner, who allegedly overcharged the bank's own customers with excess premiums on life insurance, class action lawyers have told a court.
A judge has rejected Amaca's bid for indemnity costs in a case over contributions to an asbestos class action settlement, but he did not rule on the company's novel argument that a settlement resulting from mediation could count as the outcome of litigation in awarding costs.
IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer an additional two months to address its concerns about the patent application's deficiencies.
The Commonwealth Bank of Australia on Friday pushed back against the majority of expanded claims brought by the anti-money laundering regulator and denied all allegations in the related class action.
A former financial adviser for Charter Financial Planning has been permanently barred from providing financial advice by Australia's corporate regulator after it found he deducted almost $67,000 in fees for advice he never gave.
A group of Linfox workers in Victoria has lost their bid to put a Fair Work appeal on ice while they challenge a commissioner's ruling that found in favor of the logistics giant in a dispute over their jobs.
IP Australia has denied Google's application for approval of a patent covering advertising price discounting, saying it was not a manner of manufacture and therefore not patentable.
The Australian Patent Office has shot down a patent application covering throat lozenges by consumer goods giant Reckitt-Benckiser on a challenge by rival Sanofi-Aventis.